Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Down 21.9% in December

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant drop in short interest in December. As of December 15th, there was short interest totaling 265,860 shares, a drop of 21.9% from the November 30th total of 340,426 shares. Currently, 1.7% of the shares of the stock are sold short. Based on an average daily trading volume, of 166,993 shares, the short-interest ratio is currently 1.6 days. Based on an average daily trading volume, of 166,993 shares, the short-interest ratio is currently 1.6 days. Currently, 1.7% of the shares of the stock are sold short.

Institutional Investors Weigh In On Allarity Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Citadel Advisors LLC acquired a new position in shares of Allarity Therapeutics in the 3rd quarter valued at $149,000. Private Advisor Group LLC acquired a new position in Allarity Therapeutics in the third quarter valued at about $441,000. Jane Street Group LLC purchased a new position in Allarity Therapeutics during the second quarter worth about $27,000. XTX Topco Ltd acquired a new stake in shares of Allarity Therapeutics during the second quarter valued at about $51,000. Finally, Geode Capital Management LLC increased its position in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after acquiring an additional 16,729 shares during the last quarter. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Analyst Ratings Changes

Several analysts recently issued reports on ALLR shares. Ascendiant Capital Markets upped their price objective on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Wall Street Zen upgraded Allarity Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, September 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Allarity Therapeutics in a report on Wednesday, October 8th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $9.50.

Allarity Therapeutics Price Performance

NASDAQ:ALLR opened at $1.05 on Tuesday. The firm has a market capitalization of $16.59 million, a price-to-earnings ratio of -1.78 and a beta of 0.23. The company’s 50-day moving average is $1.19 and its two-hundred day moving average is $1.24. Allarity Therapeutics has a 1-year low of $0.61 and a 1-year high of $2.35.

Allarity Therapeutics (NASDAQ:ALLR) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.04. As a group, equities analysts anticipate that Allarity Therapeutics will post -78.08 earnings per share for the current fiscal year.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.